A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
University of California, San Francisco